SPOTLIGHT -
Ruben Mesa, MD: Ruxolitinib as a Myelofibrosis Treatment
Ruben Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses treating myelofibrosis with ruxolitinib therapy.
Ruben Mesa, MD: Myelofibrosis Patients Frequently Present Symptoms
Ruben Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses the visible symptoms and diagnosis process for patients with myelofibrosis.
Naveen Pemmaraju, MD: Tagraxofusp for BPDCN
New trial results show the cytotoxin delivers clinical responses in patients with untreated or relapsed forms of the rare disease.
Naveen Pemmaraju, MD: Managing Anemia with Ruxolitinib Care
The common, concerning adverse effect requires a careful eye from clinicians and new therapy options.
New Therapy on Horizon for Rare Lung Cancer Subtype
MET inhibitor capmatinib may hold promise for a small subtype of patients with a non-small cell lung cancer, according to new ASCO 2019 findings.
Naveen Pammaraju, MD: Primary Care & JAK1 Inhibitors in Myelofibrosis
Patients with the rare cancer condition requires both a collaborative physician network and proven therapies.
Investigational Isatuximab Shows Added Benefit for Multiple Myeloma
New phase 3 trial results show the monoclonal antibody plus pomalidomide and dexamethasone improves progression free survival and overall response rate among patients with RRMM.
New Immunotherapy Blocks Key Macrophage Checkpoint in AML Care
Hu5F9-G4, aided by azacytidine, showed the potential to remove signals on cancer cells that would normally prevent a patient’s body from eliminating said cells.
Subcutaneous Daratumumab Non-Inferior, Less Burdensome than IV Regimen
Phase 3 results show the therapy plus recombinant human hyaluronidase is comparably safe and effective for patients with relapsed-refractory multiple myeloma.
Primary Care Physicians Hold Significant Value in Oncology Care
A discussion held at ASCO 2019 highlighted the statistical value associated with primary care collaboration across specialties.
Low-Income, Female Patients Likely to Face Delayed Leukemia Diagnoses
New analysis shows patients from either of these populations often take longer to be diagnosed with leukemia or lymphoma than their male or median-income counterparts.
Adenoid Cystic Carcinoma Does Not Vary According to Race, Gender
A new study shows a profound lack of genetic markers, allowing doctors to standardize treatment.
Rituximab Infusion Side Effects Abated by Rupatadine, Montelukast
A new study shows that adding this pair of drugs reduces costs and side effects while increasing efficacy.
Venetoclax with Cytarabine in Children with Relapsed or Refractory AML
Investigators from St. Jude's Children Research Hospital presented the results of the phase 1 trial at ASCO 2019 in Chicago.
VIT Improves Survival Measures in Patients with Relapsed/Refractory RMS
Investigators conducted an open-label, randomized, multi-center phase 2 study of VIT and vincristine with irinotecan without temozolomide that included 120 patients from 37 European centers.
Cost and Length of Stay in Pancreatic Cancer Patients
A study presented at ASCO 2019 examined the differences between hospitalization cost and length of stay among pancreatic cancer patients based on location of the disease.
AI: The Future of Rare Disease Treatment?
Pauline Funchain MD, shares how artificial intelligence may serve as a potential breakthrough for treating rare diseases in the future.
Using Genomic Technology to Stratify Pediatric Cancer Patients
E. Anders Kolb, MD, discusses the exciting possibilities of using genomic technologies to stratify pediatric cancer patients.
Understanding Genetics to Develop Future Treatments for Rare Cancers
Pauline Funchain MD, explains how better understanding of genetics can help shape future treatments for rare cancers.
Challenges for Treating Patients with Rare Cancers
Manmeet Ahluwalia, MD, discusses the challenges patients and providers face when it comes to rare cancers.
Molecular Events, Not Time, Define Pediatric Oncology Outcomes
E. Anders Kolb, MD, outlines the challenges in diagnosing pediatric cancers and explains how molecular events define disease outcomes.
New Drugs Needed to Target Pediatric Cancers
E. Anders Kolb, MD, emphasizes the difference between pediatric and adult cancers and the need to develop new treatments developed specifically for children.
Uncovering Rare Genetic Factors with Multiplex Germline Testing
Pauline Funchain, MD, discusses the use of multiplex germline testing for rare diseases and cancers and explains the benefits of uncovering genetic factors.
The Pivotal Role of Clinical Trials in Lymphoma Treatments
Owen A. O’Connor, MD, PhD, outlines the importance of clinical trials and reviewed strides made in lymphoma treatments.
Exploring Use of Ibrutinib/Rituximab Combination for Waldenström Macroglobulinemia
Dr Meletios A. Dimopoulos, discusses the use of ibrutinib combined with rituximab for the treatment of patients with Waldenström macroglobulinemia.
Top 5 Key Takeaways from ASCO 2018
The 2018 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, Illinois, June 1-5, 2018, featured data from numerous studies and advancements being made in rare cancers. Here are 5 key takeaways from the meeting.
Ultrasound Device Shows Efficacy for Recurrent Glioblastoma in Phase 1 Trial
Phase 1/2a clinical trial (NCT02253212) data on ultrasound-induced blood-brain barrier (BBB) opening for brain disorders like recurrent glioblastoma.
Treatment for Ultra-Rare Neuroendocrine Cancers Shows Efficacy in Phase 2 Trial
Iobenguane I 131 (AZEDRA) has been shown to be effective in patients with malignant, recurrent, or unresectable pheochromocytoma and paraganglioma (pheo/para).
Rhabdomyosarcoma Outcomes Improved with Maintenance Therapy
The use of the maintenance regimen increased both 5-year disease-free survival (DFS) and 5-year overall survival (OS) in rhabdomyosarcoma.
A Family Affair: Multiplex Germline Testing in Melanoma
Pauline Funchain MD, explains her research which focuses on assessing possible underlying genetic and familial factors in melanomas.